Admin_Adham
Jump to Key Points In this installment of Med Op-Ed: What should patients know about supplements during cancer treatment? How can oncologists approach conversations about the costs of care? And is cancer care being valued and reimbursed appropriately?
Caution on Supplements
Patients with cancer frequently consider supplements and wellness products during treatment, yet some can interfere with or reduce the effectiveness of cancer treatments, alter how the body processes medications, or intensify treatment side effects, making clinician-patient dialogue essential to guide safe use, according to Kaiwen Wang, PharmD, Dylan Singhi, BS, and Eric K. Singhi, MD, in JAMA Oncology.
The Context
- Natural does not mean safe: Certain supplements can reduce the efficacy of some cancer treatments, alter drug metabolism or elimination, increase bleeding risk, and intensify treatment side effects.
- Common evidence and quality concerns: Marketing claims may not reflect available evidence, supplements do not need to demonstrate effectiveness before sale, and product content can vary by brand, with mislabeled amounts, multiple combined ingredients, and potential drug interactions.
- Communication is key: Oncologists and patients should discuss the safety of supplements before patients take them. Oncologists may recommend vitamins or other nutritional support in specific situations, such as for patients with documented deficiencies, poor nutrition, or weight loss, emphasizing a case-by-case assessment of product safety and compatibility with the treatment plan.
In Their Own Words
“Some supplements may be safe or helpful in certain situations, while others can interfere with treatment, increase side effects, or add unnecessary cost without clear evidence that they are helping. Open conversations with the oncology team can help patients make informed decisions.”
Read it: Supplements and Wellness Products During Cancer Care
- Supplements may ↓ cancer therapy efficacy; can alter metabolism, bleeding risk, side effects.
- Supplement labels/claims often unreliable; content varies, may be mislabeled or combined.
- Oncologist-patient discussion before supplement use is essential; case-by-case safety review.
- Cost-of-care discussions occur in <25% oncology visits; often brief.
- Cancer drug prices ↑ sharply; radiation reimbursement ↓, raising value concerns.
Financial Uncertainties in Oncology
Many patients with cancer experience financial toxicity and uncertainty about the costs of care. Setting expectations and guiding choices with accessible cost information that incorporates quality data is essential across oncology, but oncologists often “lack the tools and data required to make these discussions meaningful,” according to Leila J. Mady, MD, PhD, MPH, and Seema Kacker, MD, PhD, in JAMA Otolaryngology-Head & Neck Surgery.
The Context
- Financial toxicity remains a persistent problem in oncology. Although most patients want to have discussions about costs, those conversations may not happen often enough, with one study finding that cost discussions happen in less than 1 in 4 oncology visits and are often very brief.
- Current transparency policies have not delivered usable, quality-informed prices. In one recent study, patients described costs that “were not only surprising but also unexplained,” highlighting how information asymmetries can drive uncertainty and exacerbate financial toxicity.
- Ethical and practical reforms should include treating financial risks as adverse effects requiring disclosure, as well as providing transparent pricing and formal training for discussing costs with patients. But the structural reforms and infrastructure needed to make cost information useful at the bedside remain inadequate.
In Their Own Words
“Price transparency is an informed consent imperative, and fulfilling it requires those of us at the bedside to lead the next phase of reform.”
Read it: Understanding Limits of Cost-of-Care Conversations—Managing Expectations
Growing Disparities in Cancer Therapy Payments
The cost of cancer care in the US continues to rise, with the pricing of new systemic therapies contributing substantially to the increase. At the same time, reimbursement for radiation therapy is facing cuts, raising questions about how the US healthcare system values and pays for different cancer treatment modalities, according to Chirag Shah, MD, in JAMA Oncology.
The Context
- The Viewpoint highlights disparities in how systemic therapies and radiation therapy are priced and reimbursed in the US. Median monthly launch prices for systemic therapies rose from about $11,000 in 2012-2014 to nearly $28,000 in 2023-2025, while radiation therapy reimbursement has declined over a similar period. While not a direct comparison, the figures illustrate the different ways these modalities are valued and paid for.
- The Viewpoint argues that simply increasing radiation reimbursement would not address the broader problem of rising cancer costs. It also calls for better alignment of US drug prices with those in other industrialized countries while developing value-based approaches to radiation therapy payment.
- Rethinking value in cancer care would mean looking beyond overall and progression-free survival to include outcomes such as local control, quality of life, and functional outcomes, while keeping patients at the center of decisions about cost and care.
In Their Own Words
“What we are seeing in the US currently is a distorted market with drastically different costs of care that favor new systemic therapies over other cancer treatment modalities.”
Read it: Rethinking Value in Cancer Care in the US
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
